Arrowhead Presents Phase 1 Data on ARC-520 at HepDART 2013

16-12-2013 Business Wire HealthComments (0)

Arrowhead ResearchPharmaceutical

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead presents Phase 1 data on ARC-520 at HepDART 2013 showing that ARC-520 appears to be generally safe and well-tolerated at all six dose levels studied

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top